With 0.69 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.16 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.1193 whereas the lowest price it dropped to was $1.75. The 52-week range on GRI shows that it touched its highest point at $16.92 and its lowest point at $1.10 during that stretch. It currently has a 1-year price target of $22.50. Beta for the stock currently stands at -1.47.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of GRI was up-trending over the past week, with a rise of 20.71%, but this was down by -3.77% over a month. Three-month performance surged to 45.71% while six-month performance rose 63.20%. The stock lost -85.51% in the past year, while it has lost -82.56% so far this year. A look at the trailing 12-month EPS for GRI yields -15.73 with Next year EPS estimates of -2.04. For the next quarter, that number is -1.20. This implies an EPS growth rate of 89.22% for this year and 65.91% for next year. EPS is expected to grow by 80.04% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 70.23%.
Float and Shares Shorts:
At present, 3.27 million GRI shares are outstanding with a float of 3.27 million shares on hand for trading. On 2025-10-31, short shares totaled 0.2 million, which was 799.0 higher than short shares on 1759190400. In addition to Dr. W. Marc Hertz Ph.D. as the firm’s Co-Founder, CEO, President & Director, Dr. Vipin Kumar Chaturvedi Ph.D. serves as its Co-Founder & Chief Scientific Officer.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, GRI reported revenue of $nan and operating income of $nan. The EBITDA in the recently reported quarter was $nan and diluted EPS was $nan.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With GRI analysts setting a high price target of 35.0 and a low target of 10.0, the average target price over the next 12 months is 22.5. Based on these targets, GRI could surge 1615.69% to reach the target high and rise by 390.2% to reach the target low. Reaching the average price target will result in a growth of 1002.94% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$48.11 being high and -$48.11 being low. For GRI, this leads to a yearly average estimate of -$48.11.
